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Abstract: 
 
Because numerous barriers hinder the assessment and management of chemotherapy-induced 
peripheral neuropathy in clinical practice, the Carevive Care Planning System, a novel Web-
based platform, was developed to address these barriers. It provides patients an opportunity to 
report their symptoms before their clinic visit and generates customizable care plans composed 
of evidence-based management strategies. The purpose of this study was to evaluate patient and 
provider perspectives of feasibility, usability, acceptability, and satisfaction with the Carevive 
platform. We used a single-arm, pretest/posttest, prospective design and recruited 25 women 
with breast cancer who were receiving neurotoxic chemotherapy and six advanced practice 
providers from an academic hospital. At three consecutive clinical visits, patients reported their 
neuropathy symptoms on a tablet via the Carevive system. The Diffusion of Innovations Theory 
served as an overarching evaluation framework. The Carevive platform was feasible to use. 
However, patients had higher ratings of usability, acceptability, and satisfaction with the 
platform than did the providers, who disliked the amount of time required to use the platform and 
had difficulty logging into Carevive. If issues regarding provider dissatisfaction can be 
addressed, the Carevive platform may aid in the screening of neuropathy symptoms and facilitate 
the use of evidence-based management strategies. 
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Article:  
 
In n the United States, many of the approximately 14.5 million survivors of oncological and 
hematologic malignancies have been treated with surgery, radiation, or chemotherapy.1 
Treatment-related symptoms are common and include pain, fatigue, neuropathy, dyspnea, 
nausea, and vomiting, among others.2,3 Unmanaged symptom distress can lead to increased 
hospitalizations, healthcare costs, and mortality; however, many cancer treatment–related 
symptoms are underreported by patients and underrecognized by providers.3–6 To improve 
reporting, assessment, and management of cancer treatment–related adverse effects, Carevive 
Systems (North Miami, FL) developed a care planning software program. This pilot study 
evaluated the feasibility (if it was used), usability (how easily a user could interact with the user 
interface), acceptability (how pleasant it was to use), and satisfaction (how much the user 
enjoyed it) with the Carevive care planning program, with a focus on chemotherapyinduced 
peripheral neuropathy (CIPN).7–9 
 
A common adverse effect of cancer treatment that occurs in up to 64% of individuals receiving 
neurotoxic chemotherapy (eg, platinum and taxanes),10–13 CIPN is characterized by burning, 
numbness, tingling, and/or shooting sensations in the extremities that can persist transiently or 
permanently following the completion of chemotherapy.14,15 The symptoms of CIPN may 
negatively influence physical functioning and quality of life; CIPN also may be a dose-limiting 
toxicity necessitating the decrease or cessation of chemotherapy.13,16 
 
PATIENT AND PROVIDER BARRIERS TO CIPN ASSESSMENT AND 
MANAGEMENT  
 
Early detection of CIPN through routine provider assessment may allow for prompt treatment or 
chemotherapy dose modification to improve physical function and quality of life. However, 
several barriers to optimal CIPN assessment threaten providers’ ability to provide evidence-
based care to patients at risk of CIPN-associated complications. More specifically, patients 
struggle with how to describe the symptoms they are experiencing (eg, numbness, tingling, pain), 
and providers lack the time, knowledge, and confidence to conduct comprehensive neuropathy 
assessments.11,17–20  
 
The first barrier related to management of CIPN is a lack of effective evidence-based treatments. 
The American Society of Clinical Oncology identified only one effective treatment in its 
systematic review of 48 randomized controlled trials testing 22 different pharmacological 
interventions for CIPN.11 Second, providers are unable to stay current on the rapidly mounting 
empirical literature about comprehensive management approaches for physical and 
psychological symptoms of cancer treatment.11,21 Also, evidence-based CIPN management 
guidelines are not quickly translated into clinical practice.11,16,22,23 Lastly, engaging patients in 
effective CIPN self-management requires more than disseminating patient resources.2,24,25 
Interventions are needed that will help patients to talk with their care providers and to actively 
engage in self-management strategies.  
 
The barriers to CIPN assessment and management may be addressed through the use of 
technology-based interventions that engage patients in their own care and integrate provider- and 
patient-reported clinical data with evidence-based CIPN management strategies to create 
comprehensive and tailored treatment plans. Web-based care planning programs that increase 
communication about symptoms between patients and their providers are emerging as promising 
catalysts to promote the reporting of cancer treatment– related symptoms.2,26–29 The Carevive 
Care Planning System (CPS) is a novel Web-based platform designed to help patients and 
providers collaborate to report and manage CIPN symptoms within the clinical visit workflow. 
The Carevive CPS is used to collect both patient- and provider reported data to create care plans 
consisting of personalized recommendations based on clinical practice guidelines. This platform 
addresses patient and provider barriers to CIPN assessment and promotes patient self-
management by (1) providing neuropathy self-report measures that allow patients to report their 
CIPN-related symptoms before their provider visit, (2) supplying providers with information 
about their patient’s key CIPN symptoms, and (3) generating individualized evidence-based 
CIPN management recommendations to patients and their providers. When used at the start of 
neurotoxic chemotherapy treatments and prior to each chemotherapy treatment, the Carevive 
CPS may facilitate better symptom management and improve quality of life by helping patients 
and providers identify, track, and manage symptoms of CIPN early in the course of treatment. 
 
However, many factors may impede successful integration of a novel technology into clinical 
practice. An appropriate theoretical framework may help explain these factors and their effects.30 
The Diffusion of Innovations Theory30 identifies four factors that contribute to the adoption of a 
new technology in clinical practice: (1) the innovation (eg, relative advantage, complexity, and 
observability), (2) communication channels, (3) time, and (4) the social system. The object or 
practice that is perceived as new to the individual is the innovation, which is evaluated in 
comparison to the previous method (relative advantage), in how complex it is to use 
(complexity), and how visible the results of the technology are to others (observability). 
Communication channels refer to the transmission of messages and attitudes regarding the 
innovation throughout the healthcare team. The time factor pertains to the period during which 
an individual thinks about whether to adopt the innovation into practice. Lastly, the social system 
refers to how the innovation meshes with the norms of the healthcare setting.30 Thus, successful 
implementation of the Carevive CPS would be predicated on it being viewed by patients and 
providers as (1) superior to previous methods used at the clinic as a method of assessing CIPN 
symptoms (relative advantage), (2) easy to use (complexity), (3) increasing communication 
between patients and providers about CIPN symptoms (communication channel), and (4) 
aligning with the norms of the healthcare setting (social system). 
 
The purpose of this study was to pilot test the Carevive system as a tool that may foster better 
CIPN assessment and management. The study aim was to examine patient and provider 
perspectives of feasibility, usability, acceptability, and satisfaction with the Carevive CPS. If the 
Carevive CPS demonstrated high patient and provider feasibility, usability, acceptability, and 
satisfaction, it could be further tested as an intervention to improve patient engagement in CIPN 
symptom assessment and management and provider adherence to evidence-based practice 
recommendations in an effort to improve patients’ overall quality of life. 
 
METHODS  
 
Design, Sample, and Setting  
 
The study aims were addressed via a single-arm, pretest/ posttest, prospective design. 
Convenience sampling was used to recruit 25 individuals with breast cancer and six providers. 
To be eligible for the study, patients had to be (1) 18 years or older, (2) able to speak and read 
English, (3) able to use a computer, (4) receiving neurotoxic chemotherapy (eg, paclitaxel, 
docetaxel, cisplatin, carboplatin), and (5) have a diagnosis of breast cancer (any stage). Patients 
under hospice care and patients with an expected survival of less than 1 month were excluded. 
Nurse practitioners or physician assistants who provided oncology care for at least one of the 
patients enrolled in the study were eligible. The study was approved by the study site’s 
institutional review board and was conducted at a comprehensive cancer center outpatient breast 
cancer clinic from November 21, 2014, to June 4, 2015. All enrolled patients and providers 
provided signed informed consent. 
 
Carevive Technology  
 
The Web-based Carevive CPS platform is designed to collect patient- and provider-reported data 
(eg, medical history, cancer treatment history, symptoms) at each clinical visit (see Figure 1 for 
examples of Carevive interface). Patients report their CIPN symptoms (eg, numbness, tingling, 
and associated neuropathic pain in hands or feet) via electronic versions of several common 
neuropathy measures, including the National Cancer Institute’s Patient-Reported Outcome 
Common Terminology Criteria for Adverse Events (PROCTCAE),31 the European Organisation 
for Research and Treatment of Cancer’s Quality of Life Questionnaire– Chemotherapy-Induced 
Peripheral Neuropathy Scale (QLQCIPN20),32 and two CIPN symptom screening questions. The 
PRO-CTCAE asks patients about the severity of their sensory neuropathy symptoms and how 
much their CIPN symptoms interfere with their daily activities. The 20 questions of the QLQ-
CIPN20 ask participants to rate their symptoms and functional limitations related to CIPN in 
sensory, motor, and autonomic function domains. Lastly, the CIPN symptom screening questions 
prompt patients to report the level (0–10) of numbness/tingling they were experiencing in their 
hands and feet and how much it interfered with their activities The Carevive proprietary rules 
engine configures the CIPN self-assessment questionnaires, the patient’s treatment regimen, and 
current clinical practice guidelines into automated, customized, and trackable care plans 
composed of personalized recommendations. These care plans are then reviewed by the patient’s 
provider, who may edit them to further tailor treatment recommendations and referrals. Providers 
can either accept or reject the recommendations for each symptom and the tasks associated with 
each recommendation (Figure 2). For example, a Carevive-generated recommendation for mild 
peripheral neuropathy is for individuals to discuss their CIPN symptoms with their healthcare 
team; the associated task for the patient is to view a Web site about the signs and symptoms of 
CIPN. After provider approval, the care plans are delivered electronically; the embedded links 
(tasks) direct patients to Web sites about self-management strategies and disease and treatment 
information from national organizations, such as the American Cancer Society (Figures 1 and 2). 
The CIPN management recommendations generated from this software were selected by an 
interdisciplinary team of oncology clinicians and scientists based on published literature and 
evidence-based guidelines.  
 
 
 
Measures  
 
Feasibility  
 
Patient-related feasibility data were captured automatically within the Carevive CPS using (1) 
the percentage of participants who created a Carevive account and (2) the percentage of patients 
who fully completed the Carevive self-assessment questionnaire at each visit. Provider-related 
feasibility was assessed based on the percentage of (1) providers who created a Carevive 
account, (2) providers who stated that they reviewed the care plan with their patients (Question 1 
of Provider Acceptability Survey), (3) care plans that were finalized, and (4) CIPN care plan 
recommendations and tasks that were approved for patients by providers. 
 
 
 
Usability  
 
Patient-and provider-reported ratings of Carevive CPS usability were measured using the System 
Usability Scale,33 which consists of 10 questions and uses a Likert-type response format ranging 
from 0 to 4 (strongly disagree to strongly agree). The 10 questions are divided into two sets of 
statements: five positive items and five negative items. The five negative items are reverse 
scored (4 = strongly disagree, 0 = strongly agree). The total scale is scored from 0 to 40 and then 
converted to a 0- to 100-point scale (100 represents highest usability). The System Usability 
Scale has demonstrated satisfactory internal consistency reliability with a Cronbach’s α of .91,34–
36 and structural validity has been demonstrated based on factor analysis results.36 
 
Acceptability and Satisfaction  
 
Patient-reported ratings of acceptability and satisfaction with the Carevive CPS were measured 
using the Adapted Acceptability E-Scale,37 a questionnaire consisting of six items scored on a 1- 
to 5-point scale (1 = low rating, 5 = high rating). The Acceptability E-Scale has demonstrated 
strong internal consistency reliability (Cronbach’s α = .76) when used to test an electronic 
quality-of-life and symptom assessment tool in cancer populations.37 Furthermore, its validity is 
supported based on exploratory factor analysis results.37 The questions of the Acceptability E-
Scale were adapted for the purposes of this study and determined by the study team members 
(eg, oncology clinicians, nurse scientists, PhD students). The Adapted Acceptability E-Scale 
asked patients how easy and enjoyable the Carevive CPS was to use over the course of the study 
period. 
 
For providers, acceptability and satisfaction with the Carevive CPS were evaluated through the 
administration of the Provider Acceptability Survey, a five-item questionnaire created by the 
study team specifically for use in this study (Cronbach’s α = .80). Question 1 asked providers if 
they reviewed the Carevive-generated care plan with the patient in the examination room 
(yes/no). Questions 2 through 5, which were scored using 1- to 5-point (1 = least helpful, 5 = 
most helpful) numeric rating scales, asked how helpful the Carevive CPS was in guiding patient 
interactions, promoting communication, and identifying areas of need. 
 
Informal Qualitative Feedback  
 
Study staff informally obtained feedback about the Carevive CPS from patients and providers, 
whose comments were written down and stored in an online database. Study staff also recorded 
the number of times the study providers reviewed the Carevive-generated care plan with their 
patients and reasons the providers gave if they did not. The feedback obtained from patients and 
providers was discussed at study team meetings and was primarily used to improve data 
collection processes and to identify barriers associated with the use of the Carevive CPS. 
 
Procedures  
 
The research nurse at the clinic explained the study to eligible patients after their provider visit. 
If the patient was interested, the research nurse obtained written informed consent and enrolled 
the patient in the study. Before the enrolled patient’s next provider visit, a member of the 
research team extracted baseline disease and cancer treatment information (eg, previous cancer 
diagnosis, time since current diagnosis, cancer stage) from the patient’s electronic medical record 
and entered it into the Carevive CPS. In the waiting room before each of the next three provider 
visits, the patient completed self-assessment questionnaires (eg, QLQ-CIPN20, PRO-CTCAE) 
within the Carevive platform on a tablet computer (screen size = 9.4 x 6.6 inches). In addition, at 
the first study visit, the patient reported baseline symptom and medical history and demographic 
information. After the patient completed the questionnaires, the provider generated the patient’s 
care plan by clicking on the “Generate Care Plan” button within the platform and then reviewed 
the care plan with the patient. After the examination, the care plan was delivered to the patient 
via e-mail or USB drive. At the final interaction with the Carevive CPS, study Visit 3, the patient 
also completed the Adapted Acceptability E-Scale and the System Usability Scale. Providers 
completed the Provider Acceptability Survey and the System Usability Scale electronically after 
all of the 25 enrolled patients completed the study. 
 
Statistical Analyses  
 
Data obtained from the Carevive CPS and the associated survey databases were exported into 
Excel (Microsoft, Redmond, WA) and analyzed using R version 3.2.2 (R Foundation for 
Statistical Computing, Vienna, Austria). Power analyses were not conducted because of the pilot 
nature of this study. Descriptive statistics for all quantitative data were calculated (mean, SD, 
and range). Patient-related feasibility was evaluated based on the percentage of Carevive 
accounts created and self-assessment questionnaires completed over the course of the three study 
visits. Provider-related feasibility was evaluated based on the percentage of Carevive accounts 
created and patient care plans finalized by providers. Patient- and provider-related usability was 
assessed based on System Usability Scale mean scores. Lastly patient-and provider-related 
acceptability/satisfaction was examined based on Adapted Acceptability E-Scale and Provider 
Acceptability Survey (Items 2-5) mean scores, respectively. Missing data were handled by 
imputing sample mean scores for nonmissing items. 
 
RESULTS  
 
Sample Characteristics The majority of the 25 patients enrolled in the study had a positive 
hormone receptor status (72%) and were HER2/ neu negative (52%). The most common cancer 
diagnosis was Stage IV breast cancer (36%). All patients were receiving neurotoxic 
chemotherapy, 64% had undergone cancer surgery, and 48% had completed or had planned 
radiation therapy. The majority of patients were white (80%), had at least some college education 
(88%), and had previously used a computer (100%) (Table 1). All of the six providers (five nurse 
practitioners and one physician assistant) enrolled in the study were female and had earned a 
master’s degree. The mean age was 48.33 years, and the majority were white and non-Hispanic 
(83%). On average, the providers had 13.66 years of oncology experience and 13.33 years of 
experience as a nurse practitioner or physician assistant. One patient and one provider did not 
complete the required Visit 3 surveys pertaining to usability, acceptability, and satisfaction with 
the Carevive CPS. 
 
Feasibility  
 
Feasibility was high, because most patients were able to complete the Carevive self-assessment 
questionnaires at each study visit with little help from the study staff. All enrolled patients 
created a Carevive account (25/25) and completed 74 of 75 Carevive self-assessment 
questionnaires (98.6%) over the three study visits (Table 2). All providers invited to participate 
in the study created a Carevive account (6/6); 61 of 75 patient care plans (81.3%) were reviewed 
and finalized by providers. However, only 20% of the providers who completed all of the 
outcomes assessments (n = 5) reported that they consistently reviewed the Carevive-generated 
care plans with their patients (Question 1 of Provider Acceptability Survey) (Table 2). Lastly, 
although providers accepted 100% of the peripheral neuropathy care plan recommendations, they 
accepted only 35% of the tasks associated with the recommendations at Visit 1 and 53% of the 
tasks at Visit 3. Thus, the Carevive CPS demonstrated sufficient ratings of feasibility from both a 
patient and provider perspective. 
 
 
 
Usability  
 
Patients rated the usability of the Carevive CPS higher than did providers: the mean patient score 
on the System Usability Scale was 85.00 (SD, 11.54; range, 62.50–100) (n = 24), whereas for 
providers it was 33.50 (SD, 17.19; range, 12.50–57.50) (n = 5) (Table 2). Specifically, providers 
rated the Carevive CPS as awkward to use and had the lowest mean scores on the question that 
asked if they would like to use the Carevive CPS frequently. 
 
 
 
Acceptability and Satisfaction  
 
Patients’ mean scores on the Adapted Acceptability E-Scale ranged from 4.08 (SD, 0.93) to 4.90 
(SD, 0.29) (range, 1–5) (n = 24). Mean scores on Questions 2 through 5 of the Provider 
Acceptability Survey ranged from 1.60 (SD, 0.89) to 3.20 (SD, 0.84) (range, 1–5) (n = 5) (Table 
2). Thus, patients exhibited considerably higher ratings of acceptability and satisfaction with the 
Carevive CPS than providers. In particular, providers did not believe that the Carevive CPS was 
helpful in guiding clinical interactions with patients (Item 3) or in promoting communication 
between themselves and their patients (Item 4). 
 
 
 
Qualitative Feedback  
 
Enrolled patients and providers identified several barriers to the use of the Carevive CPS. 
Patients questioned the clarity of the neuropathy items on the self-assessment questionnaire. For 
example, patients were unclear about the difference between “numbness” and “tingling” on a 
question that stated, “What was the severity of your numbness or tingling in your hands or feet at 
its worst in the past 7 days?” Patients also reported that some of the questions did not clearly 
state the time period over which they were to recall their symptoms. In addition, some patients 
did not receive the finalized care plan because (1) their e-mail address was inactive, (2) they did 
not regularly check their e-mail, or (3) they did not routinely bring their USB drive back to the 
clinic for each study visit if they had chosen that delivery option.  
 
Providers reported that they had trouble logging into the Carevive CPS on their clinic computers 
because they forgot their passwords or opened the Carevive CPS in the wrong Internet browser 
(Internet Explorer instead of Google Chrome). One provider stated, “As you know, I had 
repeated problems with the password, which undoubtedly colored my perception of this program. 
There is just no time to fiddle with a password in the middle of a busy clinic.” Furthermore, 
because of time constraints within the clinic workflow, the participating providers were 
sometimes unable to examine the study patients (a physician may have already seen the patient) 
or review the patient’s Carevive care plan. In fact, study staff documented that providers 
reviewed the care plan with the patient in the examination room only 61% of the time (28/46 
recorded observations).  
 
Providers felt that the recommendations provided by the Carevive CPS were similar to what they 
already reviewed with patients regarding CIPN symptom management. For example, for patients 
with minimal CIPN (eg, mild numbness and tingling in the hands and feet that do not interfere 
with activities of daily living), the Carevive-generated recommendation is to monitor symptoms 
closely and to contact the healthcare team if symptoms worsen. However, this recommendation 
would not add significant value beyond a verbal discussion with the patient. Providers also stated 
they would be more likely to use the Carevive CPS if they knew it was benefiting their patients. 
Lastly, study staff also frequently observed providers voicing their displeasure with the Carevive 
CPS to other clinicians. 
 
DISCUSSION  
 
This single-arm, pretest/posttest, prospective pilot study examined patients’ and providers’ 
perspectives of feasibility, usability, acceptability, and satisfaction with the Carevive CPS, a 
Web-based platform designed to improve the assessment and management of CIPN in clinical 
practice. While this study demonstrated that the Carevive CPS was feasible for both patients and 
providers to use, patients reported higher mean rates of usability, acceptability, and satisfaction 
with the Carevive CPS than did providers. Consistent with the results of this current study, recent 
evidence suggests that patients report high ratings of feasibility, usability, acceptability, and 
satisfaction with computerized oncology care planning programs.38–41 For example, in one study, 
patients with lung cancer reported their cancer treatment–related symptoms (eg, pain, dyspnea, 
anxiety, depression, constipation, insomnia) using a Web-based Symptom Assessment and 
Management Intervention (computer tablet) in the waiting room.38 Results demonstrated that 
provider adherence to the algorithm-generated recommendations was 57%, whereas the patient 
symptom assessment questionnaire completion rate was 84%, similar to the findings of the 
current study. These results suggest that further research is needed to explore why providers may 
have difficulty using computerized oncology care planning programs.  
 
The implementation of any new technology into clinical practice is challenging. Specifically, 
providers reported a greater number of challenges and complaints with the Carevive CPS use 
than patients. Providers’ unfavorable ratings of usability, acceptability, and satisfaction with the 
Carevive CPS may have been influenced by a number of challenges that can be understood in the 
context of the Diffusion of Innovations Theory.30 In terms of the relative advantage of the 
innovation itself, providers did not perceive the recommendations generated by the Carevive 
CPS to be more useful than the recommendations they were already providing in cases of 
minimal CIPN. However, because patients and providers often need more assistance and 
information to effectively manage more severe or complex symptoms, use of the Carevive CPS 
to assess and manage patients with more severe CIPN symptoms would perhaps be viewed more 
favorably.  
 
Providers also faced challenges related to the complexity of the innovation as demonstrated by 
the trouble they had logging into the platform. Related to observability, providers may not have 
adopted the Carevive CPS because they were unable to determine if their patients benefited from 
using the Carevive CPS during the study. Providers also faced challenges related to the 
communication channel. Because they frequently communicated their displeasure with the 
Carevive CPS to one another during the study period, an overall negative attitude toward 
Carevive CPS usage may have been amplified among providers. In terms of time, because the 
providers interacted with the Carevive CPS over only a few months, they may have had too little 
time to troubleshoot the challenges they encountered to determine if they could adopt the 
Carevive CPS into their daily clinical practice. Lastly, related to the social system, it is possible 
that the Carevive CPS simply did not align with the norms and values of this particular breast 
cancer clinic.  
 
Overall, the difficulties experienced by providers may have contributed to a low rate of adoption 
and lower ratings of usability, acceptability, and satisfaction. Provider ratings of usability may 
have been lower because the version of the Carevive CPS used in this study focused solely on 
CIPN. The Carevive CPS has received high ratings of patient- and provider-related usability and 
acceptability when used to assess multiple cancer symptoms (eg, sleep problems, anxiety/ 
depression, fatigue, pain, nausea).42 Specifically, providers stated that the platform helped to 
identify symptoms that patients otherwise would not tell them about, allowing them to direct the 
clinical visit to the patients’ needs and goals of care.42 Our findings may have been similar had 
we used the Carevive CPS to assess other cancer treatment–related symptoms in addition to 
CIPN. Nevertheless, this study identified several challenges associated with the implementation 
of this technology into clinical practice. Future modifications of the Carevive CPS may increase 
its usability for providers by addressing their challenges and complaints.  
 
In fact, based on the results of this study, Carevive is planning several modifications to the CPS 
to increase patient and provider usability. First, to aid in provider login, a “Forgot Password” 
button has been added on the login screen of the Carevive CPS. Second, a “Symptom Summary” 
page, which displays a summary of the patient’s answers to the Carevive self-assessment 
questionnaire, was added. This summary will allow the provider to focus on the most important 
cancer treatment–related symptoms and severity scores reported by the patients. Third, patients’ 
responses to individual symptom questions will be graphed to track symptom progression over 
time. A revised version of the Carevive CPS that incorporates these changes is being tested in a 
second phase to reevaluate patient and provider perceptions of the platform in a larger sample. 
Lastly, although it was not yet integrated in this current study, Carevive has incorporated the 
CPS into the patient’s electronic medical record and “patient portal.” This allows providers to 
simultaneously view the patient’s Carevive care plan and medical record in the examination 
room without the need to open a separate Internet browser. Furthermore, patients can complete 
the Carevive CPS self-assessment questionnaire at home before their examination and have 
access to their care plans online. The Carevive CPS may be further explored as a tool to increase 
patient engagement in CIPN symptom assessment and management and to improve provider 
adherence to CIPN quality standards. Evidence suggests that individuals who are highly engaged 
in their medical care have better treatment outcomes and lower costs of care.43  
 
The Carevive CPS may promote patient engagement in self-care by providing patients with 
personalized care plans composed of CIPN educational materials and self-management strategies 
that they can discuss with their healthcare provider. Furthermore, although documentation of 
CIPN symptom assessment is a crucial component of quality care per Joint Commission 
requirements,18 documentation of CIPN symptom assessment and management varies widely by 
provider and institution. The Carevive CPS may increase provider adherence to quality standards 
by generating individualized patient care plans that remind providers to assess for symptoms of 
CIPN (eg, numbness, tingling, pain). Personalized Carevive-generated care plans may increase 
both patient engagement in self-care and provider adherence to CIPN quality standards, which 
may improve the assessment and management of CIPN.  
 
Lastly, the use of the Carevive CPS in clinical practice may increase the availability of 
standardized patient self-report measures of neuropathy (eg, PRO-CTCAE, QLQ-CIPN20). The 
sufficient ratings of feasibility, usability, acceptability, and satisfaction with patients 
demonstrated in this study support the delivery of electronic self-report neuropathy measures. 
Providing patients an opportunity to report their neuropathy symptoms (versus physician report 
alone) is critical because evidence has demonstrated that providers consistently miss 
approximately half of the symptoms reported by patients with cancer.44–46 Furthermore, 
physician-graded neuropathy severity has not been shown to correlate highly with patient-
reported neuropathy severity.47 Thus, the Carevive CPS may improve the assessment of CIPN by 
providing patients an opportunity to report their CIPN symptoms electronically. Overall quality 
of life may also improve. A study by Basch et al48 randomly assigned 766 patients receiving 
outpatient chemotherapy either to receive usual care (symptom monitoring per clinician) or to 
report their cancer symptoms using tablet computers (nurses received e-mails when symptoms 
worsened). Results demonstrated that individuals reporting their cancer symptoms via tablet had 
greater increases in quality of life in comparison to the group reporting their cancer symptoms to 
their physician alone (P < .001).48 Although this outcome has not yet been tested, the Carevive 
CPS may increase patients’ overall quality of life by promoting the discussion of CIPN 
symptoms between patients and providers, which may lead to earlier treatment interventions.  
 
Limitations  
 
This study was conducted in a homogeneous patient population at a single outpatient clinic; thus, 
the results may not be generalizable to cancer populations other than women with breast cancer 
receiving care at a comprehensive cancer center. Also, the sample size for the number of patients 
and providers enrolled in this study was small. Moreover, because of the numerous barriers 
associated with provider-related Carevive CPS use, research staff frequently assisted providers in 
the technological aspects of accessing and completing the Carevive-generated care plans. Study 
staff assistance may have increased the providers’ perceptions of usability with the Carevive 
CPS and decreased opportunities for the providers to work through the barriers with the platform 
on their own. Lastly, because qualitative feedback was obtained informally, it is possible that not 
all of the participants had the opportunity to provide feedback about the Carevive CPS. Despite 
these limitations, this study contributes to the growing body of literature supporting the notion 
that computerized oncology care planning programs are highly rated by patients and have 
important implications for the identification and treatment of CIPN. 
 
Implications for Nursing  
 
Unmanaged cancer treatment–related symptoms can lead to decreased quality of life and poorer 
treatment outcomes.4 Beginning routine screening for symptoms early in cancer treatment will 
enable nurses to provide interventions that reduce the likelihood of adverse treatment outcomes 
and improve patients’ health-related quality of life.48–50 Symptom screening technologies such as 
the Carevive CPS may be used to increase nurse-patient communication about cancer treatment–
related symptoms and subsequently promote the early identification of cancer treatment–related 
adverse effects. Furthermore, nurses can use this technology in their practice to facilitate the use 
of evidence-based assessment and management CIPN strategies.  
 
Conclusions  
 
This pilot study examined patient- and provider-related feasibility, acceptability, usability, and 
satisfaction with the novel computerized Carevive CPS. While patients and providers both had 
high ratings of feasibility of the Carevive CPS, patients had higher ratings of acceptability, 
usability, and satisfaction than did providers. Additional research is needed to test a revised 
Carevive platform that addresses adoption barriers and to evaluate Carevive-based effects on 
CIPN symptom severity, patients’ engagement in their care, and provider adherence to evidence-
based practice recommendations.  
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